Clinical Trial Update: XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing XRP6258 plus prednisone vs mitoxantrone plus prednisone in hormone-refractory metastatic prostate cancer; results were posted December 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Mitoxantrone (mitoxantrone)
• XRP6258 (XRP6258)

Snippet

Sponsor: Sanofi | Conditions: Neoplasms, Prostatic Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2010-12-23